Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,22475517,m/z,The protonated precursor to product ion transitions monitored for bumetanide and IS were m/z 365.2→240.2 and 409.2→228.2 respectively.,Application of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of bumetanide in human plasma for a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22475517/),,365.2,9756,DB00887,Bumetanide
,22475517,m/z,The protonated precursor to product ion transitions monitored for bumetanide and IS were m/z 365.2→240.2 and 409.2→228.2 respectively.,Application of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of bumetanide in human plasma for a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22475517/),,240.2,9757,DB00887,Bumetanide
,22475517,m/z,The protonated precursor to product ion transitions monitored for bumetanide and IS were m/z 365.2→240.2 and 409.2→228.2 respectively.,Application of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of bumetanide in human plasma for a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22475517/),,409.2,9758,DB00887,Bumetanide
,22475517,m/z,The protonated precursor to product ion transitions monitored for bumetanide and IS were m/z 365.2→240.2 and 409.2→228.2 respectively.,Application of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of bumetanide in human plasma for a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22475517/),,228.2,9759,DB00887,Bumetanide
,22475517,limit of detection,The limit of detection and lower limit of quantitation of the method were 0.03 and 0.30 ng/mL respectively with a linear dynamic range of 0.30-200.0 ng/mL for bumetanide.,Application of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of bumetanide in human plasma for a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22475517/),[ng] / [ml],0.03,9760,DB00887,Bumetanide
,10692643,AUC(0-->8 h),"The AUC(0-->8 h) values of bumetanide after intraduodenal instillation were significantly smaller than AUC values after intraportal infusion at 10 (89.8 vs 569 microg min per ml) and 20 (304 vs 1230 microg min per ml) mg/kg, indicating that the first-pass organ(s) of bumetanide was intestine.",Intestinal first-pass effect of bumetanide in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692643/),[min·μg] / [ml],89.8,30836,DB00887,Bumetanide
,10692643,AUC(0-->8 h),"The AUC(0-->8 h) values of bumetanide after intraduodenal instillation were significantly smaller than AUC values after intraportal infusion at 10 (89.8 vs 569 microg min per ml) and 20 (304 vs 1230 microg min per ml) mg/kg, indicating that the first-pass organ(s) of bumetanide was intestine.",Intestinal first-pass effect of bumetanide in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692643/),[min·μg] / [ml],569,30837,DB00887,Bumetanide
,10692643,AUC(0-->8 h),"The AUC(0-->8 h) values of bumetanide after intraduodenal instillation were significantly smaller than AUC values after intraportal infusion at 10 (89.8 vs 569 microg min per ml) and 20 (304 vs 1230 microg min per ml) mg/kg, indicating that the first-pass organ(s) of bumetanide was intestine.",Intestinal first-pass effect of bumetanide in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692643/),[min·μg] / [ml],304,30838,DB00887,Bumetanide
,10692643,AUC(0-->8 h),"The AUC(0-->8 h) values of bumetanide after intraduodenal instillation were significantly smaller than AUC values after intraportal infusion at 10 (89.8 vs 569 microg min per ml) and 20 (304 vs 1230 microg min per ml) mg/kg, indicating that the first-pass organ(s) of bumetanide was intestine.",Intestinal first-pass effect of bumetanide in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692643/),[min·μg] / [ml],1230,30839,DB00887,Bumetanide
,10692643,AUC,"The AUC(0-->8 h) values of bumetanide after intraduodenal instillation were significantly smaller than AUC values after intraportal infusion at 10 (89.8 vs 569 microg min per ml) and 20 (304 vs 1230 microg min per ml) mg/kg, indicating that the first-pass organ(s) of bumetanide was intestine.",Intestinal first-pass effect of bumetanide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692643/),[min·μg] / [ml],89.8,30840,DB00887,Bumetanide
,10692643,AUC,"The AUC(0-->8 h) values of bumetanide after intraduodenal instillation were significantly smaller than AUC values after intraportal infusion at 10 (89.8 vs 569 microg min per ml) and 20 (304 vs 1230 microg min per ml) mg/kg, indicating that the first-pass organ(s) of bumetanide was intestine.",Intestinal first-pass effect of bumetanide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692643/),[min·μg] / [ml],569,30841,DB00887,Bumetanide
,10692643,AUC,"The AUC(0-->8 h) values of bumetanide after intraduodenal instillation were significantly smaller than AUC values after intraportal infusion at 10 (89.8 vs 569 microg min per ml) and 20 (304 vs 1230 microg min per ml) mg/kg, indicating that the first-pass organ(s) of bumetanide was intestine.",Intestinal first-pass effect of bumetanide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692643/),[min·μg] / [ml],304,30842,DB00887,Bumetanide
,10692643,AUC,"The AUC(0-->8 h) values of bumetanide after intraduodenal instillation were significantly smaller than AUC values after intraportal infusion at 10 (89.8 vs 569 microg min per ml) and 20 (304 vs 1230 microg min per ml) mg/kg, indicating that the first-pass organ(s) of bumetanide was intestine.",Intestinal first-pass effect of bumetanide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692643/),[min·μg] / [ml],1230,30843,DB00887,Bumetanide
,10692643,F,"The F values were 15.8 and 24.7% after intraduodenal instillation of bumetanide, 10 and 20 mg/kg, respectively.",Intestinal first-pass effect of bumetanide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692643/),%,15.8,30844,DB00887,Bumetanide
,10692643,F,"The F values were 15.8 and 24.7% after intraduodenal instillation of bumetanide, 10 and 20 mg/kg, respectively.",Intestinal first-pass effect of bumetanide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692643/),%,24.7,30845,DB00887,Bumetanide
,26189501,clearance,"The mean values were 0.063 L/h for clearance, 0.28 and 0.44 L for the central and peripheral distribution volumes, respectively, and 0.59 L/h for the distribution clearance.",Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189501/),[l] / [h],0.063,31150,DB00887,Bumetanide
,26189501,central,"The mean values were 0.063 L/h for clearance, 0.28 and 0.44 L for the central and peripheral distribution volumes, respectively, and 0.59 L/h for the distribution clearance.",Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189501/),l,0.28,31151,DB00887,Bumetanide
,26189501,central,"The mean values were 0.063 L/h for clearance, 0.28 and 0.44 L for the central and peripheral distribution volumes, respectively, and 0.59 L/h for the distribution clearance.",Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189501/),l,0.44,31152,DB00887,Bumetanide
,26189501,distribution clearance,"The mean values were 0.063 L/h for clearance, 0.28 and 0.44 L for the central and peripheral distribution volumes, respectively, and 0.59 L/h for the distribution clearance.",Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189501/),[l] / [h],0.59,31153,DB00887,Bumetanide
,8218964,AUC,"The values of AUC, t1/2 and MRT increased 79.0, 417, and 633 per cent, respectively, and CL and CLNR decreased 44.0 and 41.2 per cent, respectively, in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),%,417,34105,DB00887,Bumetanide
,8218964,t1/2,"The values of AUC, t1/2 and MRT increased 79.0, 417, and 633 per cent, respectively, and CL and CLNR decreased 44.0 and 41.2 per cent, respectively, in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),%,417,34106,DB00887,Bumetanide
,8218964,t1/2,"The values of AUC, t1/2 and MRT increased 79.0, 417, and 633 per cent, respectively, and CL and CLNR decreased 44.0 and 41.2 per cent, respectively, in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),%,633,34107,DB00887,Bumetanide
,8218964,MRT,"The values of AUC, t1/2 and MRT increased 79.0, 417, and 633 per cent, respectively, and CL and CLNR decreased 44.0 and 41.2 per cent, respectively, in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),%,417,34108,DB00887,Bumetanide
,8218964,MRT,"The values of AUC, t1/2 and MRT increased 79.0, 417, and 633 per cent, respectively, and CL and CLNR decreased 44.0 and 41.2 per cent, respectively, in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),%,633,34109,DB00887,Bumetanide
,8218964,CLNR,"The decreased CLNR in water deprived rats could be due to decreased nonrenal metabolism of bumetanide; it could be supported that the amounts of glucuronide conjugate of bumetanide (52.5 vs 12.9 micrograms), desbutylbumetanide (170 vs 113 micrograms) and its glucuronide conjugation (191 vs 125 micrograms), and sum of the three metabolites (414 vs 229 micrograms), which are expressed in terms of bumetanide excreted in 24 h urine, decreased significantly in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),,12,34110,DB00887,Bumetanide
,8218964,CLNR,"The decreased CLNR in water deprived rats could be due to decreased nonrenal metabolism of bumetanide; it could be supported that the amounts of glucuronide conjugate of bumetanide (52.5 vs 12.9 micrograms), desbutylbumetanide (170 vs 113 micrograms) and its glucuronide conjugation (191 vs 125 micrograms), and sum of the three metabolites (414 vs 229 micrograms), which are expressed in terms of bumetanide excreted in 24 h urine, decreased significantly in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),μ,170,34111,DB00887,Bumetanide
,8218964,CLNR,"The decreased CLNR in water deprived rats could be due to decreased nonrenal metabolism of bumetanide; it could be supported that the amounts of glucuronide conjugate of bumetanide (52.5 vs 12.9 micrograms), desbutylbumetanide (170 vs 113 micrograms) and its glucuronide conjugation (191 vs 125 micrograms), and sum of the three metabolites (414 vs 229 micrograms), which are expressed in terms of bumetanide excreted in 24 h urine, decreased significantly in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),μ,113,34112,DB00887,Bumetanide
,8218964,CLNR,"The decreased CLNR in water deprived rats could be due to decreased nonrenal metabolism of bumetanide; it could be supported that the amounts of glucuronide conjugate of bumetanide (52.5 vs 12.9 micrograms), desbutylbumetanide (170 vs 113 micrograms) and its glucuronide conjugation (191 vs 125 micrograms), and sum of the three metabolites (414 vs 229 micrograms), which are expressed in terms of bumetanide excreted in 24 h urine, decreased significantly in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),μ,191,34113,DB00887,Bumetanide
,8218964,CLNR,"The decreased CLNR in water deprived rats could be due to decreased nonrenal metabolism of bumetanide; it could be supported that the amounts of glucuronide conjugate of bumetanide (52.5 vs 12.9 micrograms), desbutylbumetanide (170 vs 113 micrograms) and its glucuronide conjugation (191 vs 125 micrograms), and sum of the three metabolites (414 vs 229 micrograms), which are expressed in terms of bumetanide excreted in 24 h urine, decreased significantly in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),μ,125,34114,DB00887,Bumetanide
,8218964,CLNR,"The decreased CLNR in water deprived rats could be due to decreased nonrenal metabolism of bumetanide; it could be supported that the amounts of glucuronide conjugate of bumetanide (52.5 vs 12.9 micrograms), desbutylbumetanide (170 vs 113 micrograms) and its glucuronide conjugation (191 vs 125 micrograms), and sum of the three metabolites (414 vs 229 micrograms), which are expressed in terms of bumetanide excreted in 24 h urine, decreased significantly in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),,41,34115,DB00887,Bumetanide
,8218964,CLNR,"The decreased CLNR in water deprived rats could be due to decreased nonrenal metabolism of bumetanide; it could be supported that the amounts of glucuronide conjugate of bumetanide (52.5 vs 12.9 micrograms), desbutylbumetanide (170 vs 113 micrograms) and its glucuronide conjugation (191 vs 125 micrograms), and sum of the three metabolites (414 vs 229 micrograms), which are expressed in terms of bumetanide excreted in 24 h urine, decreased significantly in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),,229,34116,DB00887,Bumetanide
,8218964,urine outputs,"The 8-h urine outputs per 100 g body weight (4.32 vs 1.34 ml) also reduced significantly in water deprived rats, and it might be due to significantly reduced amounts of bumetanide excreted in 8 h urine (90.9 vs 25.7 micrograms) and/or reduced kidney function in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),ml,4.32,34117,DB00887,Bumetanide
,8218964,urine outputs,"The 8-h urine outputs per 100 g body weight (4.32 vs 1.34 ml) also reduced significantly in water deprived rats, and it might be due to significantly reduced amounts of bumetanide excreted in 8 h urine (90.9 vs 25.7 micrograms) and/or reduced kidney function in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),ml,1.34,34118,DB00887,Bumetanide
,8218964,CLIot,The kidney function based on CLIot (9.87 vs 2.14 ml min-1 kg-1) reduced significantly in water deprived rats.,Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),[ml] / [kg·min],9.87,34119,DB00887,Bumetanide
,8218964,CLIot,The kidney function based on CLIot (9.87 vs 2.14 ml min-1 kg-1) reduced significantly in water deprived rats.,Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),[ml] / [kg·min],2.14,34120,DB00887,Bumetanide
,8218964,urinary excretions,"The 8-h urinary excretions of sodium (0.430 vs 0.0818 mmol), potassium (0.567 vs 0.270 mmol), and chloride (0.549 vs 0.0624 mmol) per 100 g body weight also reduced significantly in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),mM,0.430,34121,DB00887,Bumetanide
,8218964,urinary excretions,"The 8-h urinary excretions of sodium (0.430 vs 0.0818 mmol), potassium (0.567 vs 0.270 mmol), and chloride (0.549 vs 0.0624 mmol) per 100 g body weight also reduced significantly in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),mM,0.0818,34122,DB00887,Bumetanide
,8218964,urinary excretions,"The 8-h urinary excretions of sodium (0.430 vs 0.0818 mmol), potassium (0.567 vs 0.270 mmol), and chloride (0.549 vs 0.0624 mmol) per 100 g body weight also reduced significantly in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),mM,0.567,34123,DB00887,Bumetanide
,8218964,urinary excretions,"The 8-h urinary excretions of sodium (0.430 vs 0.0818 mmol), potassium (0.567 vs 0.270 mmol), and chloride (0.549 vs 0.0624 mmol) per 100 g body weight also reduced significantly in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),mM,0.270,34124,DB00887,Bumetanide
,8218964,urinary excretions,"The 8-h urinary excretions of sodium (0.430 vs 0.0818 mmol), potassium (0.567 vs 0.270 mmol), and chloride (0.549 vs 0.0624 mmol) per 100 g body weight also reduced significantly in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),mM,0.549,34125,DB00887,Bumetanide
,8218964,urinary excretions,"The 8-h urinary excretions of sodium (0.430 vs 0.0818 mmol), potassium (0.567 vs 0.270 mmol), and chloride (0.549 vs 0.0624 mmol) per 100 g body weight also reduced significantly in water deprived rats.",Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218964/),mM,0.0624,34126,DB00887,Bumetanide
,6342640,peak serum concentration,"The peak serum concentration of piretanide (1-2 h after drug administration) was 510-880 ng/ml, independent of renal function.",The pharmacokinetics and diuretic effects of piretanide in chronic renal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6342640/),[ng] / [ml],510-880,59697,DB00887,Bumetanide
,6342640,Elimination half life (t1/2),"Elimination half life (t1/2) was 1.2-4.1 h, area under the curves (AUC(0,24)) 1.63-2.44 micrograms ml-1 h, volume of distribution (Vz) 0.30--0.741#kg, total plasma clearance (CL) 122.8-184.0 ml/min and renal clearance (CLR) 1.5-5.2 ml/min.",The pharmacokinetics and diuretic effects of piretanide in chronic renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6342640/),h,1.2-4.1,59698,DB00887,Bumetanide
,6342640,"area under the curves (AUC(0,24))","Elimination half life (t1/2) was 1.2-4.1 h, area under the curves (AUC(0,24)) 1.63-2.44 micrograms ml-1 h, volume of distribution (Vz) 0.30--0.741#kg, total plasma clearance (CL) 122.8-184.0 ml/min and renal clearance (CLR) 1.5-5.2 ml/min.",The pharmacokinetics and diuretic effects of piretanide in chronic renal insufficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6342640/),[h·μg] / [ml],1.63-2.44,59699,DB00887,Bumetanide
,6342640,volume of distribution (Vz),"Elimination half life (t1/2) was 1.2-4.1 h, area under the curves (AUC(0,24)) 1.63-2.44 micrograms ml-1 h, volume of distribution (Vz) 0.30--0.741#kg, total plasma clearance (CL) 122.8-184.0 ml/min and renal clearance (CLR) 1.5-5.2 ml/min.",The pharmacokinetics and diuretic effects of piretanide in chronic renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6342640/),#kg,0.30,59700,DB00887,Bumetanide
,6342640,total plasma clearance (CL),"Elimination half life (t1/2) was 1.2-4.1 h, area under the curves (AUC(0,24)) 1.63-2.44 micrograms ml-1 h, volume of distribution (Vz) 0.30--0.741#kg, total plasma clearance (CL) 122.8-184.0 ml/min and renal clearance (CLR) 1.5-5.2 ml/min.",The pharmacokinetics and diuretic effects of piretanide in chronic renal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6342640/),[ml] / [min],122.8-184.0,59701,DB00887,Bumetanide
,6342640,renal clearance (CLR),"Elimination half life (t1/2) was 1.2-4.1 h, area under the curves (AUC(0,24)) 1.63-2.44 micrograms ml-1 h, volume of distribution (Vz) 0.30--0.741#kg, total plasma clearance (CL) 122.8-184.0 ml/min and renal clearance (CLR) 1.5-5.2 ml/min.",The pharmacokinetics and diuretic effects of piretanide in chronic renal insufficiency. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6342640/),[ml] / [min],1.5-5.2,59702,DB00887,Bumetanide
,6644592,flow rate,Lactated Ringer's solution was administered intravenously throughout both treatments at a flow rate of 2 ml/min to avoid fluid and electrolyte depletion.,Determinants of bumetanide response in the dog: effect of indomethacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6644592/),[ml] / [min],2,65963,DB00887,Bumetanide
,1447670,Total plasma,"Total plasma and renal clearances for bumetanide were 0.63 +/- 0.11 and 0.16 +/- 0.04 ml/min per kilogram, respectively.",Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1447670/),[ml] / [kg·min],0.63,69376,DB00887,Bumetanide
,1447670,renal clearances,"Total plasma and renal clearances for bumetanide were 0.63 +/- 0.11 and 0.16 +/- 0.04 ml/min per kilogram, respectively.",Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1447670/),[ml] / [kg·min],0.16,69377,DB00887,Bumetanide
,1447670,steady-state volume of distribution,The steady-state volume of distribution (0.44 +/- 0.03 L/kg) and the elimination half-life (13.2 +/- 3.8 hours) were greater than similar values reported in previous studies of bumetanide disposition in premature and term neonates who were not treated with extracorporeal membrane oxygenation.,Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1447670/),[l] / [kg],0.44,69378,DB00887,Bumetanide
,1447670,elimination half-life,The steady-state volume of distribution (0.44 +/- 0.03 L/kg) and the elimination half-life (13.2 +/- 3.8 hours) were greater than similar values reported in previous studies of bumetanide disposition in premature and term neonates who were not treated with extracorporeal membrane oxygenation.,Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1447670/),h,13.2,69379,DB00887,Bumetanide
,1447670,Nonrenal elimination,Nonrenal elimination of bumetanide was variable (47.2% to 96.9%) but higher than expected; this may explain the relatively brief diuretic and kaliuretic response.,Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1447670/),,47,69380,DB00887,Bumetanide
≥,26673740,transport ratio,"Using efflux transport studies, we show that bumetanide is a transported substrate of human OAT3, exhibiting a transport ratio of ≥1.5, which is attenuated by OAT3 inhibitors.",In vitro bidirectional permeability studies identify pharmacokinetic limitations of NKCC1 inhibitor bumetanide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26673740/),,1.5,75347,DB00887,Bumetanide
,3180632,bioavailability,"The extent of bioavailability was 81%, with a variability of 20% to 25% about the mean for both groups.","Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180632/),%,81,81147,DB00887,Bumetanide
,884919,apparent volume of distribution,Its average apparent volume of distribution was 25 L.,Diuretic effect and metabolism of bumetanide in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/884919/),l,25,84808,DB00887,Bumetanide
,884919,plasma half-life,Bumetanide was quickly eliminated by metabolism and urinary excretion with a plasma half-life of 1.5 hr.,Diuretic effect and metabolism of bumetanide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/884919/),h,1.5,84809,DB00887,Bumetanide
,9395836,serum clearance,"Estimated serum clearance was 0.2-1.0 ml/min.kg (range), volume of distribution was 0.22 l/kg (range 0.11-0.32 l/kg), and the harmonic mean half-life was 6-7 h (range of 4-19 h).",The pharmacokinetics of bumetanide in the newborn infant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9395836/),[ml] / [kg·min],0.2-1.0,88163,DB00887,Bumetanide
,9395836,volume of distribution,"Estimated serum clearance was 0.2-1.0 ml/min.kg (range), volume of distribution was 0.22 l/kg (range 0.11-0.32 l/kg), and the harmonic mean half-life was 6-7 h (range of 4-19 h).",The pharmacokinetics of bumetanide in the newborn infant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9395836/),[l] / [kg],0.22,88164,DB00887,Bumetanide
,9395836,half-life,"Estimated serum clearance was 0.2-1.0 ml/min.kg (range), volume of distribution was 0.22 l/kg (range 0.11-0.32 l/kg), and the harmonic mean half-life was 6-7 h (range of 4-19 h).",The pharmacokinetics of bumetanide in the newborn infant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9395836/),h,6-7,88165,DB00887,Bumetanide
,6491914,"t 1/2, alpha","The pharmacokinetics of bumetanide after intravenous administration was characterized by a biexponential equation, including an initial disposition phase (t 1/2, alpha = 5.1 min), followed by a slower elimination phase (t 1/2, beta = 44 min).","Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491914/),min,5.1,93337,DB00887,Bumetanide
,6491914,"t 1/2, beta","The pharmacokinetics of bumetanide after intravenous administration was characterized by a biexponential equation, including an initial disposition phase (t 1/2, alpha = 5.1 min), followed by a slower elimination phase (t 1/2, beta = 44 min).","Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491914/),min,44,93338,DB00887,Bumetanide
,6491914,maximum plasma concentrations,"Bumetanide is rapidly absorbed via the intramuscular and oral routes, with mean +/- SD maximum plasma concentrations of 38.2 +/- 9.8 (intramuscular), 34.0 +/- 10.6 (oral solution), and 30.9 +/- 14.6 ng/mL (tablet) achieved within 0.34 +/- 0.23, 0.76 +/- 0.27, and 1.8 +/- 1.2 h after dosing, respectively.","Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491914/),,38.2,93339,DB00887,Bumetanide
,6491914,maximum plasma concentrations,"Bumetanide is rapidly absorbed via the intramuscular and oral routes, with mean +/- SD maximum plasma concentrations of 38.2 +/- 9.8 (intramuscular), 34.0 +/- 10.6 (oral solution), and 30.9 +/- 14.6 ng/mL (tablet) achieved within 0.34 +/- 0.23, 0.76 +/- 0.27, and 1.8 +/- 1.2 h after dosing, respectively.","Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491914/),,34.0,93340,DB00887,Bumetanide
,6491914,maximum plasma concentrations,"Bumetanide is rapidly absorbed via the intramuscular and oral routes, with mean +/- SD maximum plasma concentrations of 38.2 +/- 9.8 (intramuscular), 34.0 +/- 10.6 (oral solution), and 30.9 +/- 14.6 ng/mL (tablet) achieved within 0.34 +/- 0.23, 0.76 +/- 0.27, and 1.8 +/- 1.2 h after dosing, respectively.","Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491914/),,30.9,93341,DB00887,Bumetanide
,6491914,half-lives,"The drug is rapidly eliminated from the body after intravenous, intramuscular, oral solution, and oral tablet administrations, with half-lives ranging from 24-86, 47-139, 27-71, and 26-99 min, respectively.","Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491914/),min,24-86,93342,DB00887,Bumetanide
,6491914,half-lives,"The drug is rapidly eliminated from the body after intravenous, intramuscular, oral solution, and oral tablet administrations, with half-lives ranging from 24-86, 47-139, 27-71, and 26-99 min, respectively.","Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491914/),min,47-139,93343,DB00887,Bumetanide
,6491914,half-lives,"The drug is rapidly eliminated from the body after intravenous, intramuscular, oral solution, and oral tablet administrations, with half-lives ranging from 24-86, 47-139, 27-71, and 26-99 min, respectively.","Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491914/),min,27-71,93344,DB00887,Bumetanide
,6491914,half-lives,"The drug is rapidly eliminated from the body after intravenous, intramuscular, oral solution, and oral tablet administrations, with half-lives ranging from 24-86, 47-139, 27-71, and 26-99 min, respectively.","Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491914/),min,26-99,93345,DB00887,Bumetanide
,6491914,absolute bioavailability,"The extent of bioavailability of bumetanide from the tablet and oral solution dosage forms are equivalent, and the absolute bioavailability of the intramuscular and oral preparations are approximately 100 and 80%, respectively.","Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491914/),%,100,93346,DB00887,Bumetanide
,6491914,absolute bioavailability,"The extent of bioavailability of bumetanide from the tablet and oral solution dosage forms are equivalent, and the absolute bioavailability of the intramuscular and oral preparations are approximately 100 and 80%, respectively.","Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491914/),%,80,93347,DB00887,Bumetanide
,8218971,AUC0-12 h,"After oral administration, the AUC0-12 h decreased significantly (186 versus 335 micrograms min ml-1) in SHRs and this resulted in decreased F(15.4 versus 23.6 and 2.78 versus 5.76% using two equations) in SHRs when compared with the control Wistar rats, although none of the other pharmacokinetic parameters varied significantly between SHRs and Wistar rats.",Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt induced hypertensive rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218971/),[min·μg] / [ml],186,106558,DB00887,Bumetanide
,8218971,AUC0-12 h,"After oral administration, the AUC0-12 h decreased significantly (186 versus 335 micrograms min ml-1) in SHRs and this resulted in decreased F(15.4 versus 23.6 and 2.78 versus 5.76% using two equations) in SHRs when compared with the control Wistar rats, although none of the other pharmacokinetic parameters varied significantly between SHRs and Wistar rats.",Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt induced hypertensive rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218971/),[min·μg] / [ml],335,106559,DB00887,Bumetanide
,8873688,percent,The mean percent of bumetanide recovered in the urine from 0 to 12 hours was 40% +/- 15% of the administered dose.,Pharmacokinetics of bumetanide in critically ill infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8873688/),%,40,109488,DB00887,Bumetanide
,843423,absorption half-life,2. The absorption of oral [14C]-bumetanide was rapid (absorption half-life 0.61 h) and complete with a urinary recovery of about 80% of the intravenous or oral dose during 48 h.,Fate of [14C]-bumetanide in man. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/843423/),h,0.61,118648,DB00887,Bumetanide
,843423,half-life of elimination (T 1/2 beta),3. The elimination of [14C]-bumetanide was rapid with a half-life of elimination (T 1/2 beta) of 1.5 h.,Fate of [14C]-bumetanide in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/843423/),h,1.5,118649,DB00887,Bumetanide
,843423,Protein bound fraction,4. Protein bound fraction of [14C]-bumetanide in plasma was 95%.,Fate of [14C]-bumetanide in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/843423/),%,95,118650,DB00887,Bumetanide
,6872415,bioavailability,"Consequently, bumetanide has an estimated bioavailability of 80% (approximately 40% for furosemide).",Bumetanide and furosemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872415/),%,80,118669,DB00887,Bumetanide
,6872415,bioavailability,"Consequently, bumetanide has an estimated bioavailability of 80% (approximately 40% for furosemide).",Bumetanide and furosemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872415/),%,40,118670,DB00887,Bumetanide
,6872415,dose inducing half-maximal response,"The relationship between the logarithm of the urinary bumetanide excretion rate and the logarithm of the sodium excretion rate was described by a sigmoid-shaped dose-response curve, with a dose inducing half-maximal response of 1 +/- 0.04 micrograms/min; it was 69.8 micrograms/min for furosemide.",Bumetanide and furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872415/),[μg] / [min],1,118671,DB00887,Bumetanide
,6872415,dose inducing half-maximal response,"The relationship between the logarithm of the urinary bumetanide excretion rate and the logarithm of the sodium excretion rate was described by a sigmoid-shaped dose-response curve, with a dose inducing half-maximal response of 1 +/- 0.04 micrograms/min; it was 69.8 micrograms/min for furosemide.",Bumetanide and furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872415/),[μg] / [min],69.8,118672,DB00887,Bumetanide
,9485520,Initial arterial to venous concentration ratios,"Initial arterial to venous concentration ratios at 5 sec after injection were the highest with the values of 1410, 246, 4.25, and 351 for rabbits 1-4, respectively.",Arterial and venous blood sampling in pharmacokinetic studies: bumetanide in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9485520/),,1410,124295,DB00887,Bumetanide
,9485520,Initial arterial to venous concentration ratios,"Initial arterial to venous concentration ratios at 5 sec after injection were the highest with the values of 1410, 246, 4.25, and 351 for rabbits 1-4, respectively.",Arterial and venous blood sampling in pharmacokinetic studies: bumetanide in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9485520/),,246,124296,DB00887,Bumetanide
,9485520,Initial arterial to venous concentration ratios,"Initial arterial to venous concentration ratios at 5 sec after injection were the highest with the values of 1410, 246, 4.25, and 351 for rabbits 1-4, respectively.",Arterial and venous blood sampling in pharmacokinetic studies: bumetanide in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9485520/),,4.25,124297,DB00887,Bumetanide
,9485520,Initial arterial to venous concentration ratios,"Initial arterial to venous concentration ratios at 5 sec after injection were the highest with the values of 1410, 246, 4.25, and 351 for rabbits 1-4, respectively.",Arterial and venous blood sampling in pharmacokinetic studies: bumetanide in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9485520/),,351,124298,DB00887,Bumetanide
,9350065,water reabsorption,"When plasma potassium concentration was raised from 2.6 +/- 0.2 to 7.9 +/- 0.2 mmol l-1, water reabsorption decreased from 23.9 +/- 2.9 to 19.8 +/- 2.2 ml min-1, whereas lithium reabsorption increased from 10.5 +/- 2.3 to 18.1 +/- 2.3 mumol min-1, at constant glomerular filtration rate.",Dissociation between water and lithium transport during acute changes in plasma potassium concentration in dog kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350065/),[ml] / [min],23.9,139282,DB00887,Bumetanide
,9350065,water reabsorption,"When plasma potassium concentration was raised from 2.6 +/- 0.2 to 7.9 +/- 0.2 mmol l-1, water reabsorption decreased from 23.9 +/- 2.9 to 19.8 +/- 2.2 ml min-1, whereas lithium reabsorption increased from 10.5 +/- 2.3 to 18.1 +/- 2.3 mumol min-1, at constant glomerular filtration rate.",Dissociation between water and lithium transport during acute changes in plasma potassium concentration in dog kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350065/),[ml] / [min],19.8,139283,DB00887,Bumetanide
,9350065,reabsorption,"When plasma potassium concentration was raised from 2.6 +/- 0.2 to 7.9 +/- 0.2 mmol l-1, water reabsorption decreased from 23.9 +/- 2.9 to 19.8 +/- 2.2 ml min-1, whereas lithium reabsorption increased from 10.5 +/- 2.3 to 18.1 +/- 2.3 mumol min-1, at constant glomerular filtration rate.",Dissociation between water and lithium transport during acute changes in plasma potassium concentration in dog kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350065/),[μM] / [min],10.5,139284,DB00887,Bumetanide
,9350065,reabsorption,"When plasma potassium concentration was raised from 2.6 +/- 0.2 to 7.9 +/- 0.2 mmol l-1, water reabsorption decreased from 23.9 +/- 2.9 to 19.8 +/- 2.2 ml min-1, whereas lithium reabsorption increased from 10.5 +/- 2.3 to 18.1 +/- 2.3 mumol min-1, at constant glomerular filtration rate.",Dissociation between water and lithium transport during acute changes in plasma potassium concentration in dog kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350065/),[μM] / [min],18.1,139285,DB00887,Bumetanide
,6849758,F (bioavailability),"5 Absorption rates were not significantly altered in either group and the values of F (bioavailability) were 0.82 and 0.95 for the patients with renal disease and hepatic disease, respectively.",The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849758/),,0.82,148115,DB00887,Bumetanide
,6849758,F (bioavailability),"5 Absorption rates were not significantly altered in either group and the values of F (bioavailability) were 0.82 and 0.95 for the patients with renal disease and hepatic disease, respectively.",The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849758/),,0.95,148116,DB00887,Bumetanide
,6875808,flow rate,Lactated Ringer's solution was administered by vein throughout both treatments at a flow rate of 2 ml/min to avoid fluid and electrolyte depletion.,Determinants of bumetanide response in the dog: effect of probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6875808/),[ml] / [min],2,151848,DB00887,Bumetanide
,8971430,peak plasma concentration,3. Breakfast significantly reduced the peak plasma concentration of frusemide from 2.35 +/- 0.49 to 0.51 +/- 0.19 mg l-1 (95% confidence intervals (95% CI) = 1.39 to 2.28 mg l-1) and delayed the time to peak concentration from 0.69 +/- 0.21 to 1.91 +/- 0.93 h (95% CI = 0.41 to 2.03 h).,Effect of food on the absorption of frusemide and bumetanide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),[mg] / [l],2.35,163693,DB00887,Bumetanide
,8971430,peak plasma concentration,3. Breakfast significantly reduced the peak plasma concentration of frusemide from 2.35 +/- 0.49 to 0.51 +/- 0.19 mg l-1 (95% confidence intervals (95% CI) = 1.39 to 2.28 mg l-1) and delayed the time to peak concentration from 0.69 +/- 0.21 to 1.91 +/- 0.93 h (95% CI = 0.41 to 2.03 h).,Effect of food on the absorption of frusemide and bumetanide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),[mg] / [l],0.51,163694,DB00887,Bumetanide
,8971430,time to peak concentration,3. Breakfast significantly reduced the peak plasma concentration of frusemide from 2.35 +/- 0.49 to 0.51 +/- 0.19 mg l-1 (95% confidence intervals (95% CI) = 1.39 to 2.28 mg l-1) and delayed the time to peak concentration from 0.69 +/- 0.21 to 1.91 +/- 0.93 h (95% CI = 0.41 to 2.03 h).,Effect of food on the absorption of frusemide and bumetanide in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),h,0.69,163695,DB00887,Bumetanide
,8971430,time to peak concentration,3. Breakfast significantly reduced the peak plasma concentration of frusemide from 2.35 +/- 0.49 to 0.51 +/- 0.19 mg l-1 (95% confidence intervals (95% CI) = 1.39 to 2.28 mg l-1) and delayed the time to peak concentration from 0.69 +/- 0.21 to 1.91 +/- 0.93 h (95% CI = 0.41 to 2.03 h).,Effect of food on the absorption of frusemide and bumetanide in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),h,1.91,163696,DB00887,Bumetanide
,8971430,oral bioavailability,The oral bioavailability of frusemide was significantly reduced by approximately 30% (75.6 +/- 10.6 to 43.2 +/- 16.8%; 95% CI = 13.5 to 51.4%).,Effect of food on the absorption of frusemide and bumetanide in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),%,75.6,163697,DB00887,Bumetanide
,8971430,oral bioavailability,The oral bioavailability of frusemide was significantly reduced by approximately 30% (75.6 +/- 10.6 to 43.2 +/- 16.8%; 95% CI = 13.5 to 51.4%).,Effect of food on the absorption of frusemide and bumetanide in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),%,43.2,163698,DB00887,Bumetanide
,8971430,peak concentration,"4. With bumetanide, the meal also significantly reduced the peak concentration from 0.097 +/- 0.015 to 0.036 +/- 0.012 mg l-1 (95% CI = 0.048 to 0.073 mg l-1) and delayed the time to peak from 0.53 +/- 0.08 to 1.36 +/- 0.72 h (95% CI = 0.23 to 1.44 h).",Effect of food on the absorption of frusemide and bumetanide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),[mg] / [l],0.097,163699,DB00887,Bumetanide
,8971430,peak concentration,"4. With bumetanide, the meal also significantly reduced the peak concentration from 0.097 +/- 0.015 to 0.036 +/- 0.012 mg l-1 (95% CI = 0.048 to 0.073 mg l-1) and delayed the time to peak from 0.53 +/- 0.08 to 1.36 +/- 0.72 h (95% CI = 0.23 to 1.44 h).",Effect of food on the absorption of frusemide and bumetanide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),[mg] / [l],0.036,163700,DB00887,Bumetanide
,8971430,time to peak,"4. With bumetanide, the meal also significantly reduced the peak concentration from 0.097 +/- 0.015 to 0.036 +/- 0.012 mg l-1 (95% CI = 0.048 to 0.073 mg l-1) and delayed the time to peak from 0.53 +/- 0.08 to 1.36 +/- 0.72 h (95% CI = 0.23 to 1.44 h).",Effect of food on the absorption of frusemide and bumetanide in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),h,0.53,163701,DB00887,Bumetanide
,8971430,time to peak,"4. With bumetanide, the meal also significantly reduced the peak concentration from 0.097 +/- 0.015 to 0.036 +/- 0.012 mg l-1 (95% CI = 0.048 to 0.073 mg l-1) and delayed the time to peak from 0.53 +/- 0.08 to 1.36 +/- 0.72 h (95% CI = 0.23 to 1.44 h).",Effect of food on the absorption of frusemide and bumetanide in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),h,1.36,163702,DB00887,Bumetanide
,9824779,total clearance,"The plasma pharmacokinetics of bumetanide revealed mean +/- standard deviation values for total clearance and apparent volume of distribution of 3.9 +/- 2.4 mL/min/kg and 0.74 +/- 0.54 L/kg, respectively.",Pharmacokinetics and pharmacodynamics of bumetanide in critically ill pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824779/),[ml] / [kg·min],3.9,181838,DB00887,Bumetanide
,9824779,apparent volume of distribution,"The plasma pharmacokinetics of bumetanide revealed mean +/- standard deviation values for total clearance and apparent volume of distribution of 3.9 +/- 2.4 mL/min/kg and 0.74 +/- 0.54 L/kg, respectively.",Pharmacokinetics and pharmacodynamics of bumetanide in critically ill pediatric patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824779/),[l] / [kg],0.74,181839,DB00887,Bumetanide
,9474471,bioavailablity,"It is well absorbed and yields a bioavailablity of about 80% in healthy individuals, even higher in patients with oedema.",Clinical pharmacokinetics and pharmacodynamics of torasemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9474471/),%,80,183581,DB00887,Bumetanide
,9474471,volume of distribution,The volume of distribution of torasemide was determined as 0.2 L/kg as compared with 0.11 to 0.18 L/kg for furosemide.,Clinical pharmacokinetics and pharmacodynamics of torasemide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9474471/),[l] / [kg],0.2,183582,DB00887,Bumetanide
,9474471,volume of distribution,The volume of distribution of torasemide was determined as 0.2 L/kg as compared with 0.11 to 0.18 L/kg for furosemide.,Clinical pharmacokinetics and pharmacodynamics of torasemide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9474471/),[l] / [kg],0.11 to 0.18,183583,DB00887,Bumetanide
,9474471,maximum natriuretic effect,The maximum natriuretic effect of all loop diuretics amounts to about 3 mmol Na+/min.,Clinical pharmacokinetics and pharmacodynamics of torasemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9474471/),[mM·na+] / [min],3,183584,DB00887,Bumetanide
,3761422,elimination half-life,"The elimination half-life was found to be 6.3 min, the volume of distribution at steady state 68 ml/kg and the total plasma clearance 10.9 ml/min/kg.",Pharmacokinetics and diuretic effect of bumetanide following intravenous and intramuscular administration to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761422/),min,6.3,191542,DB00887,Bumetanide
,3761422,volume of distribution at steady state,"The elimination half-life was found to be 6.3 min, the volume of distribution at steady state 68 ml/kg and the total plasma clearance 10.9 ml/min/kg.",Pharmacokinetics and diuretic effect of bumetanide following intravenous and intramuscular administration to horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761422/),[ml] / [kg],68,191543,DB00887,Bumetanide
,3761422,total plasma clearance,"The elimination half-life was found to be 6.3 min, the volume of distribution at steady state 68 ml/kg and the total plasma clearance 10.9 ml/min/kg.",Pharmacokinetics and diuretic effect of bumetanide following intravenous and intramuscular administration to horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761422/),[ml] / [kg·min],10.9,191544,DB00887,Bumetanide
,3761422,bioavailability,"Given by the intramuscular (i.m.) route, bumetanide was rapidly absorbed; bioavailability was 70-80%.",Pharmacokinetics and diuretic effect of bumetanide following intravenous and intramuscular administration to horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761422/),%,70-80,191545,DB00887,Bumetanide
,3761422,plasma half-life,i.m. administration of bumetanide prolonged its plasma half-life (11-27 min) and enhanced and prolonged its diuretic effect.,Pharmacokinetics and diuretic effect of bumetanide following intravenous and intramuscular administration to horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761422/),min,11-27,191546,DB00887,Bumetanide
,8364470,bioavailability,"The bioavailability (absolute), expressed as the ratio of the area under the plasma concentration-time curve (AUC) following oral administration of bumetanide, was 39% that of intravenous administration.",Enhanced absorption of bumetanide from suppositories containing weak acids in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364470/),%,39,196342,DB00887,Bumetanide
,8364470,absolute bioavailability,"Each absolute bioavailability following rectal administration of the suppositories with 5% citric acid and 5% tartaric acid was 52% and 42%, respectively.",Enhanced absorption of bumetanide from suppositories containing weak acids in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364470/),%,52,196343,DB00887,Bumetanide
,8364470,absolute bioavailability,"Each absolute bioavailability following rectal administration of the suppositories with 5% citric acid and 5% tartaric acid was 52% and 42%, respectively.",Enhanced absorption of bumetanide from suppositories containing weak acids in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364470/),%,42,196344,DB00887,Bumetanide
,3709028,bioavailability,"Although bioavailability was relatively consistent among the HS (0.664 +/- 0.112) and CRF (0.689 +/- 0.149) groups, the absorption-time profiles were more irregular for both groups.","Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709028/),,0.664,203348,DB00887,Bumetanide
,3709028,bioavailability,"Although bioavailability was relatively consistent among the HS (0.664 +/- 0.112) and CRF (0.689 +/- 0.149) groups, the absorption-time profiles were more irregular for both groups.","Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709028/),,0.689,203349,DB00887,Bumetanide
,1873508,nonrenal clearance,The nonrenal clearance (19.3 vs 29.6 ml min-1 per kg) of bumetanide increased significantly in PB treated rats.,Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and the pharmacodynamics of bumetanide in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1873508/),[ml] / [kg·min],19.3,204437,DB00887,Bumetanide
,1873508,nonrenal clearance,The nonrenal clearance (19.3 vs 29.6 ml min-1 per kg) of bumetanide increased significantly in PB treated rats.,Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and the pharmacodynamics of bumetanide in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1873508/),[ml] / [kg·min],29.6,204438,DB00887,Bumetanide
,6883908,Elimination t1/2s,Elimination t1/2s were 60 to 90 min.,Effects of piretanide in normal subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883908/),min,60 to 90,206365,DB00887,Bumetanide
,6883908,Renal clearance rate,Renal clearance rate was 90 to 100 ml/min and oral clearance was 200 ml/min.,Effects of piretanide in normal subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883908/),[ml] / [min],90 to 100,206366,DB00887,Bumetanide
,6883908,oral clearance,Renal clearance rate was 90 to 100 ml/min and oral clearance was 200 ml/min.,Effects of piretanide in normal subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883908/),[ml] / [min],200,206367,DB00887,Bumetanide
,6883908,half-maximal response,The piretanide dose that induced half-maximal response was 12.1 +/- 2.6 micrograms/min; it is 69.8 micrograms/min for furosemide and 1 micrograms/min for bumetanide.,Effects of piretanide in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883908/),[μg] / [min],12.1,206368,DB00887,Bumetanide
,6883908,half-maximal response,The piretanide dose that induced half-maximal response was 12.1 +/- 2.6 micrograms/min; it is 69.8 micrograms/min for furosemide and 1 micrograms/min for bumetanide.,Effects of piretanide in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883908/),[μg] / [min],69.8,206369,DB00887,Bumetanide
,6883908,half-maximal response,The piretanide dose that induced half-maximal response was 12.1 +/- 2.6 micrograms/min; it is 69.8 micrograms/min for furosemide and 1 micrograms/min for bumetanide.,Effects of piretanide in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883908/),[μg] / [min],1,206370,DB00887,Bumetanide
,8490111,CL,"For example, the mean values of CL (13.6, 25.3 vs 18.2 ml min-1 kg-1), MRT (9.70, 10.6 vs 21.8 min), Vss (128, 217 vs 378 ml kg-1), and CLNR (2.71, 9.24 vs 6.44 ml min-1 kg-1) increased when the same dose of bumetanide was infused in 1 h or 4 h.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),[ml] / [kg·min],13.6,208052,DB00887,Bumetanide
,8490111,CL,"For example, the mean values of CL (13.6, 25.3 vs 18.2 ml min-1 kg-1), MRT (9.70, 10.6 vs 21.8 min), Vss (128, 217 vs 378 ml kg-1), and CLNR (2.71, 9.24 vs 6.44 ml min-1 kg-1) increased when the same dose of bumetanide was infused in 1 h or 4 h.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),[ml] / [kg·min],25.3,208053,DB00887,Bumetanide
,8490111,CL,"For example, the mean values of CL (13.6, 25.3 vs 18.2 ml min-1 kg-1), MRT (9.70, 10.6 vs 21.8 min), Vss (128, 217 vs 378 ml kg-1), and CLNR (2.71, 9.24 vs 6.44 ml min-1 kg-1) increased when the same dose of bumetanide was infused in 1 h or 4 h.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),[ml] / [kg·min],18.2,208054,DB00887,Bumetanide
,8490111,MRT,"For example, the mean values of CL (13.6, 25.3 vs 18.2 ml min-1 kg-1), MRT (9.70, 10.6 vs 21.8 min), Vss (128, 217 vs 378 ml kg-1), and CLNR (2.71, 9.24 vs 6.44 ml min-1 kg-1) increased when the same dose of bumetanide was infused in 1 h or 4 h.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),min,9.70,208055,DB00887,Bumetanide
,8490111,MRT,"For example, the mean values of CL (13.6, 25.3 vs 18.2 ml min-1 kg-1), MRT (9.70, 10.6 vs 21.8 min), Vss (128, 217 vs 378 ml kg-1), and CLNR (2.71, 9.24 vs 6.44 ml min-1 kg-1) increased when the same dose of bumetanide was infused in 1 h or 4 h.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),min,10.6,208056,DB00887,Bumetanide
,8490111,MRT,"For example, the mean values of CL (13.6, 25.3 vs 18.2 ml min-1 kg-1), MRT (9.70, 10.6 vs 21.8 min), Vss (128, 217 vs 378 ml kg-1), and CLNR (2.71, 9.24 vs 6.44 ml min-1 kg-1) increased when the same dose of bumetanide was infused in 1 h or 4 h.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),min,21.8,208057,DB00887,Bumetanide
,8490111,Vss,"For example, the mean values of CL (13.6, 25.3 vs 18.2 ml min-1 kg-1), MRT (9.70, 10.6 vs 21.8 min), Vss (128, 217 vs 378 ml kg-1), and CLNR (2.71, 9.24 vs 6.44 ml min-1 kg-1) increased when the same dose of bumetanide was infused in 1 h or 4 h.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),[ml] / [kg],128,208058,DB00887,Bumetanide
,8490111,Vss,"For example, the mean values of CL (13.6, 25.3 vs 18.2 ml min-1 kg-1), MRT (9.70, 10.6 vs 21.8 min), Vss (128, 217 vs 378 ml kg-1), and CLNR (2.71, 9.24 vs 6.44 ml min-1 kg-1) increased when the same dose of bumetanide was infused in 1 h or 4 h.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),[ml] / [kg],217,208059,DB00887,Bumetanide
,8490111,Vss,"For example, the mean values of CL (13.6, 25.3 vs 18.2 ml min-1 kg-1), MRT (9.70, 10.6 vs 21.8 min), Vss (128, 217 vs 378 ml kg-1), and CLNR (2.71, 9.24 vs 6.44 ml min-1 kg-1) increased when the same dose of bumetanide was infused in 1 h or 4 h.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),[ml] / [kg],378,208060,DB00887,Bumetanide
,8490111,CLNR,"For example, the mean values of CL (13.6, 25.3 vs 18.2 ml min-1 kg-1), MRT (9.70, 10.6 vs 21.8 min), Vss (128, 217 vs 378 ml kg-1), and CLNR (2.71, 9.24 vs 6.44 ml min-1 kg-1) increased when the same dose of bumetanide was infused in 1 h or 4 h.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),[ml] / [kg·min],2.71,208061,DB00887,Bumetanide
,8490111,CLNR,"For example, the mean values of CL (13.6, 25.3 vs 18.2 ml min-1 kg-1), MRT (9.70, 10.6 vs 21.8 min), Vss (128, 217 vs 378 ml kg-1), and CLNR (2.71, 9.24 vs 6.44 ml min-1 kg-1) increased when the same dose of bumetanide was infused in 1 h or 4 h.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),[ml] / [kg·min],9.24,208062,DB00887,Bumetanide
,8490111,CLNR,"For example, the mean values of CL (13.6, 25.3 vs 18.2 ml min-1 kg-1), MRT (9.70, 10.6 vs 21.8 min), Vss (128, 217 vs 378 ml kg-1), and CLNR (2.71, 9.24 vs 6.44 ml min-1 kg-1) increased when the same dose of bumetanide was infused in 1 h or 4 h.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),[ml] / [kg·min],6.44,208063,DB00887,Bumetanide
,8490111,total amounts of urinary excretion,"The diuretic effects (urine outputs and urinary excretions of sodium and chloride) increased significantly in 1 and 4 h of infusion although the total amounts of urinary excretion of unchanged bumetanide were 21.8 and 20.5 per cent lower in treatments II and III, respectively, when compared with the value in treatment I; the mean values of 8-h urine outputs were 373, 922, and 1030 ml for 10s, 1 h, and 4 h of infusion, respectively, and the corresponding values for 24-h sodium excretions were 49.0, 82.8, and 121 mmol, and for chloride were 47.5, 71.1, and 114 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),%,21.8,208064,DB00887,Bumetanide
,8490111,total amounts of urinary excretion,"The diuretic effects (urine outputs and urinary excretions of sodium and chloride) increased significantly in 1 and 4 h of infusion although the total amounts of urinary excretion of unchanged bumetanide were 21.8 and 20.5 per cent lower in treatments II and III, respectively, when compared with the value in treatment I; the mean values of 8-h urine outputs were 373, 922, and 1030 ml for 10s, 1 h, and 4 h of infusion, respectively, and the corresponding values for 24-h sodium excretions were 49.0, 82.8, and 121 mmol, and for chloride were 47.5, 71.1, and 114 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),%,20.5,208065,DB00887,Bumetanide
,8490111,urine outputs,"The diuretic effects (urine outputs and urinary excretions of sodium and chloride) increased significantly in 1 and 4 h of infusion although the total amounts of urinary excretion of unchanged bumetanide were 21.8 and 20.5 per cent lower in treatments II and III, respectively, when compared with the value in treatment I; the mean values of 8-h urine outputs were 373, 922, and 1030 ml for 10s, 1 h, and 4 h of infusion, respectively, and the corresponding values for 24-h sodium excretions were 49.0, 82.8, and 121 mmol, and for chloride were 47.5, 71.1, and 114 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),ml,373,208066,DB00887,Bumetanide
,8490111,urine outputs,"The diuretic effects (urine outputs and urinary excretions of sodium and chloride) increased significantly in 1 and 4 h of infusion although the total amounts of urinary excretion of unchanged bumetanide were 21.8 and 20.5 per cent lower in treatments II and III, respectively, when compared with the value in treatment I; the mean values of 8-h urine outputs were 373, 922, and 1030 ml for 10s, 1 h, and 4 h of infusion, respectively, and the corresponding values for 24-h sodium excretions were 49.0, 82.8, and 121 mmol, and for chloride were 47.5, 71.1, and 114 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),ml,922,208067,DB00887,Bumetanide
,8490111,urine outputs,"The diuretic effects (urine outputs and urinary excretions of sodium and chloride) increased significantly in 1 and 4 h of infusion although the total amounts of urinary excretion of unchanged bumetanide were 21.8 and 20.5 per cent lower in treatments II and III, respectively, when compared with the value in treatment I; the mean values of 8-h urine outputs were 373, 922, and 1030 ml for 10s, 1 h, and 4 h of infusion, respectively, and the corresponding values for 24-h sodium excretions were 49.0, 82.8, and 121 mmol, and for chloride were 47.5, 71.1, and 114 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),ml,1030,208068,DB00887,Bumetanide
,8490111,sodium excretions,"The diuretic effects (urine outputs and urinary excretions of sodium and chloride) increased significantly in 1 and 4 h of infusion although the total amounts of urinary excretion of unchanged bumetanide were 21.8 and 20.5 per cent lower in treatments II and III, respectively, when compared with the value in treatment I; the mean values of 8-h urine outputs were 373, 922, and 1030 ml for 10s, 1 h, and 4 h of infusion, respectively, and the corresponding values for 24-h sodium excretions were 49.0, 82.8, and 121 mmol, and for chloride were 47.5, 71.1, and 114 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),mM,49.0,208069,DB00887,Bumetanide
,8490111,sodium excretions,"The diuretic effects (urine outputs and urinary excretions of sodium and chloride) increased significantly in 1 and 4 h of infusion although the total amounts of urinary excretion of unchanged bumetanide were 21.8 and 20.5 per cent lower in treatments II and III, respectively, when compared with the value in treatment I; the mean values of 8-h urine outputs were 373, 922, and 1030 ml for 10s, 1 h, and 4 h of infusion, respectively, and the corresponding values for 24-h sodium excretions were 49.0, 82.8, and 121 mmol, and for chloride were 47.5, 71.1, and 114 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),mM,82.8,208070,DB00887,Bumetanide
,8490111,sodium excretions,"The diuretic effects (urine outputs and urinary excretions of sodium and chloride) increased significantly in 1 and 4 h of infusion although the total amounts of urinary excretion of unchanged bumetanide were 21.8 and 20.5 per cent lower in treatments II and III, respectively, when compared with the value in treatment I; the mean values of 8-h urine outputs were 373, 922, and 1030 ml for 10s, 1 h, and 4 h of infusion, respectively, and the corresponding values for 24-h sodium excretions were 49.0, 82.8, and 121 mmol, and for chloride were 47.5, 71.1, and 114 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),mM,121,208071,DB00887,Bumetanide
,8490111,sodium excretions,"The diuretic effects (urine outputs and urinary excretions of sodium and chloride) increased significantly in 1 and 4 h of infusion although the total amounts of urinary excretion of unchanged bumetanide were 21.8 and 20.5 per cent lower in treatments II and III, respectively, when compared with the value in treatment I; the mean values of 8-h urine outputs were 373, 922, and 1030 ml for 10s, 1 h, and 4 h of infusion, respectively, and the corresponding values for 24-h sodium excretions were 49.0, 82.8, and 121 mmol, and for chloride were 47.5, 71.1, and 114 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),mM,47.5,208072,DB00887,Bumetanide
,8490111,sodium excretions,"The diuretic effects (urine outputs and urinary excretions of sodium and chloride) increased significantly in 1 and 4 h of infusion although the total amounts of urinary excretion of unchanged bumetanide were 21.8 and 20.5 per cent lower in treatments II and III, respectively, when compared with the value in treatment I; the mean values of 8-h urine outputs were 373, 922, and 1030 ml for 10s, 1 h, and 4 h of infusion, respectively, and the corresponding values for 24-h sodium excretions were 49.0, 82.8, and 121 mmol, and for chloride were 47.5, 71.1, and 114 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),mM,71.1,208073,DB00887,Bumetanide
,8490111,sodium excretions,"The diuretic effects (urine outputs and urinary excretions of sodium and chloride) increased significantly in 1 and 4 h of infusion although the total amounts of urinary excretion of unchanged bumetanide were 21.8 and 20.5 per cent lower in treatments II and III, respectively, when compared with the value in treatment I; the mean values of 8-h urine outputs were 373, 922, and 1030 ml for 10s, 1 h, and 4 h of infusion, respectively, and the corresponding values for 24-h sodium excretions were 49.0, 82.8, and 121 mmol, and for chloride were 47.5, 71.1, and 114 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490111/),mM,114,208074,DB00887,Bumetanide
,6641097,diuresis at steady state,Continuous intravenous infusion of bumetanide (200 micrograms/hr) gave an average diuresis at steady state of 15 +/- 3 ml/min.,Coupling between renal tubular secretion and effect of bumetanide. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641097/),[ml] / [min],15,210441,DB00887,Bumetanide
,6641097,plasma,"Corresponding plasma concentration, urinary excretion rate, and renal clearance of bumetanide averaged 14.3 +/- 2.3 ng/ml, 64 +/- 31 micrograms/30 min, and 145 +/- 59 ml/min.",Coupling between renal tubular secretion and effect of bumetanide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641097/),[ng] / [ml],14.3,210442,DB00887,Bumetanide
,6641097,urinary excretion rate,"Corresponding plasma concentration, urinary excretion rate, and renal clearance of bumetanide averaged 14.3 +/- 2.3 ng/ml, 64 +/- 31 micrograms/30 min, and 145 +/- 59 ml/min.",Coupling between renal tubular secretion and effect of bumetanide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641097/),[μg] / [30·min],64,210443,DB00887,Bumetanide
,6641097,renal clearance,"Corresponding plasma concentration, urinary excretion rate, and renal clearance of bumetanide averaged 14.3 +/- 2.3 ng/ml, 64 +/- 31 micrograms/30 min, and 145 +/- 59 ml/min.",Coupling between renal tubular secretion and effect of bumetanide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641097/),[ml] / [min],145,210444,DB00887,Bumetanide
,6641097,plasma concentration,"Average plasma concentration rose to 41.7 +/- 8.1 ng/ml, whereas renal clearance and urinary excretion rate fell to 15.1% and 29.5% of control.",Coupling between renal tubular secretion and effect of bumetanide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641097/),[ng] / [ml],41.7,210445,DB00887,Bumetanide
,8027946,t1/2,"After i.v. dose, the pharmacokinetic parameters of bumetanide, such as t1/2 (21.4, 53.8 vs. 127 min), CL (35.8, 19.1 vs. 13.4 ml/min per kg), CLNR (35.2, 17.8 vs. 12.6 ml/min per kg) and VSS (392, 250 vs. 274 ml/kg) were dose-dependent at the dose range studied.",Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8027946/),min,21.4,223892,DB00887,Bumetanide
,8027946,t1/2,"After i.v. dose, the pharmacokinetic parameters of bumetanide, such as t1/2 (21.4, 53.8 vs. 127 min), CL (35.8, 19.1 vs. 13.4 ml/min per kg), CLNR (35.2, 17.8 vs. 12.6 ml/min per kg) and VSS (392, 250 vs. 274 ml/kg) were dose-dependent at the dose range studied.",Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8027946/),min,53.8,223893,DB00887,Bumetanide
,8027946,t1/2,"After i.v. dose, the pharmacokinetic parameters of bumetanide, such as t1/2 (21.4, 53.8 vs. 127 min), CL (35.8, 19.1 vs. 13.4 ml/min per kg), CLNR (35.2, 17.8 vs. 12.6 ml/min per kg) and VSS (392, 250 vs. 274 ml/kg) were dose-dependent at the dose range studied.",Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8027946/),min,127,223894,DB00887,Bumetanide
,8027946,CL,"After i.v. dose, the pharmacokinetic parameters of bumetanide, such as t1/2 (21.4, 53.8 vs. 127 min), CL (35.8, 19.1 vs. 13.4 ml/min per kg), CLNR (35.2, 17.8 vs. 12.6 ml/min per kg) and VSS (392, 250 vs. 274 ml/kg) were dose-dependent at the dose range studied.",Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8027946/),[ml] / [kg·min],35.8,223895,DB00887,Bumetanide
,8027946,CL,"After i.v. dose, the pharmacokinetic parameters of bumetanide, such as t1/2 (21.4, 53.8 vs. 127 min), CL (35.8, 19.1 vs. 13.4 ml/min per kg), CLNR (35.2, 17.8 vs. 12.6 ml/min per kg) and VSS (392, 250 vs. 274 ml/kg) were dose-dependent at the dose range studied.",Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8027946/),[ml] / [kg·min],19.1,223896,DB00887,Bumetanide
,8027946,CL,"After i.v. dose, the pharmacokinetic parameters of bumetanide, such as t1/2 (21.4, 53.8 vs. 127 min), CL (35.8, 19.1 vs. 13.4 ml/min per kg), CLNR (35.2, 17.8 vs. 12.6 ml/min per kg) and VSS (392, 250 vs. 274 ml/kg) were dose-dependent at the dose range studied.",Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8027946/),[ml] / [kg·min],13.4,223897,DB00887,Bumetanide
,8027946,CLNR,"After i.v. dose, the pharmacokinetic parameters of bumetanide, such as t1/2 (21.4, 53.8 vs. 127 min), CL (35.8, 19.1 vs. 13.4 ml/min per kg), CLNR (35.2, 17.8 vs. 12.6 ml/min per kg) and VSS (392, 250 vs. 274 ml/kg) were dose-dependent at the dose range studied.",Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8027946/),[ml] / [kg·min],35.2,223898,DB00887,Bumetanide
,8027946,CLNR,"After i.v. dose, the pharmacokinetic parameters of bumetanide, such as t1/2 (21.4, 53.8 vs. 127 min), CL (35.8, 19.1 vs. 13.4 ml/min per kg), CLNR (35.2, 17.8 vs. 12.6 ml/min per kg) and VSS (392, 250 vs. 274 ml/kg) were dose-dependent at the dose range studied.",Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8027946/),[ml] / [kg·min],17.8,223899,DB00887,Bumetanide
,8027946,CLNR,"After i.v. dose, the pharmacokinetic parameters of bumetanide, such as t1/2 (21.4, 53.8 vs. 127 min), CL (35.8, 19.1 vs. 13.4 ml/min per kg), CLNR (35.2, 17.8 vs. 12.6 ml/min per kg) and VSS (392, 250 vs. 274 ml/kg) were dose-dependent at the dose range studied.",Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8027946/),[ml] / [kg·min],12.6,223900,DB00887,Bumetanide
,8027946,VSS,"After i.v. dose, the pharmacokinetic parameters of bumetanide, such as t1/2 (21.4, 53.8 vs. 127 min), CL (35.8, 19.1 vs. 13.4 ml/min per kg), CLNR (35.2, 17.8 vs. 12.6 ml/min per kg) and VSS (392, 250 vs. 274 ml/kg) were dose-dependent at the dose range studied.",Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8027946/),[ml] / [kg],392,223901,DB00887,Bumetanide
,8027946,VSS,"After i.v. dose, the pharmacokinetic parameters of bumetanide, such as t1/2 (21.4, 53.8 vs. 127 min), CL (35.8, 19.1 vs. 13.4 ml/min per kg), CLNR (35.2, 17.8 vs. 12.6 ml/min per kg) and VSS (392, 250 vs. 274 ml/kg) were dose-dependent at the dose range studied.",Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8027946/),[ml] / [kg],250,223902,DB00887,Bumetanide
,8027946,VSS,"After i.v. dose, the pharmacokinetic parameters of bumetanide, such as t1/2 (21.4, 53.8 vs. 127 min), CL (35.8, 19.1 vs. 13.4 ml/min per kg), CLNR (35.2, 17.8 vs. 12.6 ml/min per kg) and VSS (392, 250 vs. 274 ml/kg) were dose-dependent at the dose range studied.",Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8027946/),[ml] / [kg],274,223903,DB00887,Bumetanide
,6763204,apparent half-life,"The apparent half-life is 1.2-1.5 hr, and the volume of distribution is about 25 liters.","Pharmacology, therapeutic efficacy, and adverse effects of bumetanide, a new ""loop"" diuretic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6763204/),h,1.2-1.5,231975,DB00887,Bumetanide
,6763204,volume of distribution,"The apparent half-life is 1.2-1.5 hr, and the volume of distribution is about 25 liters.","Pharmacology, therapeutic efficacy, and adverse effects of bumetanide, a new ""loop"" diuretic. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6763204/),l,25,231976,DB00887,Bumetanide
,6763204,Plasma clearance,Plasma clearance is 228-255 ml/min.,"Pharmacology, therapeutic efficacy, and adverse effects of bumetanide, a new ""loop"" diuretic. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6763204/),[ml] / [min],228-255,231977,DB00887,Bumetanide
,11745917,plasma protein binding,"After intravenous administration of bumetanide, 10 mg/kg, to analbuminemic rats, the plasma protein binding of bumetanide was 36.8% in the rats mainly due to considerable binding to alpha- and beta-globulins (this value, 36.8%, was considerably greater than only 12% for furosemide), and hence the percentages of intravenous dose of bumetanide excreted in 6 h urine as unchanged drug was 16.0% in the rat (this value was considerably greater than only 7% for furosemide).",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),%,36.8,232609,DB00887,Bumetanide
,11745917,plasma protein binding,"After intravenous administration of bumetanide, 10 mg/kg, to analbuminemic rats, the plasma protein binding of bumetanide was 36.8% in the rats mainly due to considerable binding to alpha- and beta-globulins (this value, 36.8%, was considerably greater than only 12% for furosemide), and hence the percentages of intravenous dose of bumetanide excreted in 6 h urine as unchanged drug was 16.0% in the rat (this value was considerably greater than only 7% for furosemide).",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),%,36.,232610,DB00887,Bumetanide
,11745917,area under the plasma concentration-time curve from time zero to time infinity,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[min·μg] / [ml],1012,232611,DB00887,Bumetanide
,11745917,area under the plasma concentration-time curve from time zero to time infinity,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[min·μg] / [ml],2472,232612,DB00887,Bumetanide
,11745917,both renal clearance,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[ml] / [kg·min],1.49,232613,DB00887,Bumetanide
,11745917,both renal clearance,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[ml] / [kg·min],0.275,232614,DB00887,Bumetanide
,11745917,nonrenal clearance,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[ml] / [kg·min],8.30,232615,DB00887,Bumetanide
,11745917,nonrenal clearance,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[ml] / [kg·min],3.71,232616,DB00887,Bumetanide
,11745917,terminal half-life,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),min,9.94,232617,DB00887,Bumetanide
,11745917,terminal half-life,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),min,22.4,232618,DB00887,Bumetanide
,11745917,mean residence time,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),min,4.25,232619,DB00887,Bumetanide
,11745917,mean residence time,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),min,5.90,232620,DB00887,Bumetanide
,11745917,total body clearance,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[ml] / [kg·min],9.88,232621,DB00887,Bumetanide
,11745917,total body clearance,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[ml] / [kg·min],4.05,232622,DB00887,Bumetanide
,11745917,urinary excretion,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),μg,559,232623,DB00887,Bumetanide
,11745917,urinary excretion,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),μg,261,232624,DB00887,Bumetanide
,7420267,half-lives,"The mean half-lives associated with each exponent were 5.9 min, 46 min, and 3.1 hr, respectively.",Pharmacokinetics of intravenously administered bumetanide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420267/),min,5.9,234734,DB00887,Bumetanide
,7420267,half-lives,"The mean half-lives associated with each exponent were 5.9 min, 46 min, and 3.1 hr, respectively.",Pharmacokinetics of intravenously administered bumetanide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420267/),min,46,234735,DB00887,Bumetanide
,7420267,half-lives,"The mean half-lives associated with each exponent were 5.9 min, 46 min, and 3.1 hr, respectively.",Pharmacokinetics of intravenously administered bumetanide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420267/),h,3.1,234736,DB00887,Bumetanide
,7420267,total plasma clearance,"The total plasma clearance averaged 228 ml/min, with renal clearance about one-half of this value.",Pharmacokinetics of intravenously administered bumetanide in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420267/),[ml] / [min],228,234737,DB00887,Bumetanide
,7420267,recovery,"The recovery of unchanged bumetanide in urine over 2 days was 47% of the dose, while the total recovery of radioactivity in urine averaged 82% of dose.",Pharmacokinetics of intravenously administered bumetanide in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420267/),%,47,234738,DB00887,Bumetanide
,7420267,total recovery of radioactivity,"The recovery of unchanged bumetanide in urine over 2 days was 47% of the dose, while the total recovery of radioactivity in urine averaged 82% of dose.",Pharmacokinetics of intravenously administered bumetanide in man. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420267/),%,82,234739,DB00887,Bumetanide
,7738809,urine output,"For example, the mean 8-h urine output values were 189, 317, 2170, and 306 mL for treatments I-IV, respectively, the corresponding 8-h sodium excretion values were 9.19, 16.5, 88.8, and 15.7 mmol, and the chloride excretion values were 10.8, 33.7, 77.4, and 11.7 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous bumetanide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738809/),ml,189,235006,DB00887,Bumetanide
,7738809,urine output,"For example, the mean 8-h urine output values were 189, 317, 2170, and 306 mL for treatments I-IV, respectively, the corresponding 8-h sodium excretion values were 9.19, 16.5, 88.8, and 15.7 mmol, and the chloride excretion values were 10.8, 33.7, 77.4, and 11.7 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous bumetanide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738809/),ml,317,235007,DB00887,Bumetanide
,7738809,urine output,"For example, the mean 8-h urine output values were 189, 317, 2170, and 306 mL for treatments I-IV, respectively, the corresponding 8-h sodium excretion values were 9.19, 16.5, 88.8, and 15.7 mmol, and the chloride excretion values were 10.8, 33.7, 77.4, and 11.7 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous bumetanide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738809/),ml,2170,235008,DB00887,Bumetanide
,7738809,urine output,"For example, the mean 8-h urine output values were 189, 317, 2170, and 306 mL for treatments I-IV, respectively, the corresponding 8-h sodium excretion values were 9.19, 16.5, 88.8, and 15.7 mmol, and the chloride excretion values were 10.8, 33.7, 77.4, and 11.7 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous bumetanide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738809/),ml,306,235009,DB00887,Bumetanide
,7738809,sodium excretion,"For example, the mean 8-h urine output values were 189, 317, 2170, and 306 mL for treatments I-IV, respectively, the corresponding 8-h sodium excretion values were 9.19, 16.5, 88.8, and 15.7 mmol, and the chloride excretion values were 10.8, 33.7, 77.4, and 11.7 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous bumetanide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738809/),mM,9.19,235010,DB00887,Bumetanide
,7738809,sodium excretion,"For example, the mean 8-h urine output values were 189, 317, 2170, and 306 mL for treatments I-IV, respectively, the corresponding 8-h sodium excretion values were 9.19, 16.5, 88.8, and 15.7 mmol, and the chloride excretion values were 10.8, 33.7, 77.4, and 11.7 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous bumetanide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738809/),mM,16.5,235011,DB00887,Bumetanide
,7738809,sodium excretion,"For example, the mean 8-h urine output values were 189, 317, 2170, and 306 mL for treatments I-IV, respectively, the corresponding 8-h sodium excretion values were 9.19, 16.5, 88.8, and 15.7 mmol, and the chloride excretion values were 10.8, 33.7, 77.4, and 11.7 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous bumetanide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738809/),mM,88.8,235012,DB00887,Bumetanide
,7738809,sodium excretion,"For example, the mean 8-h urine output values were 189, 317, 2170, and 306 mL for treatments I-IV, respectively, the corresponding 8-h sodium excretion values were 9.19, 16.5, 88.8, and 15.7 mmol, and the chloride excretion values were 10.8, 33.7, 77.4, and 11.7 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous bumetanide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738809/),mM,15.7,235013,DB00887,Bumetanide
,7738809,chloride excretion,"For example, the mean 8-h urine output values were 189, 317, 2170, and 306 mL for treatments I-IV, respectively, the corresponding 8-h sodium excretion values were 9.19, 16.5, 88.8, and 15.7 mmol, and the chloride excretion values were 10.8, 33.7, 77.4, and 11.7 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous bumetanide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738809/),mM,10.8,235014,DB00887,Bumetanide
,7738809,chloride excretion,"For example, the mean 8-h urine output values were 189, 317, 2170, and 306 mL for treatments I-IV, respectively, the corresponding 8-h sodium excretion values were 9.19, 16.5, 88.8, and 15.7 mmol, and the chloride excretion values were 10.8, 33.7, 77.4, and 11.7 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous bumetanide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738809/),mM,33.7,235015,DB00887,Bumetanide
,7738809,chloride excretion,"For example, the mean 8-h urine output values were 189, 317, 2170, and 306 mL for treatments I-IV, respectively, the corresponding 8-h sodium excretion values were 9.19, 16.5, 88.8, and 15.7 mmol, and the chloride excretion values were 10.8, 33.7, 77.4, and 11.7 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous bumetanide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738809/),mM,77.4,235016,DB00887,Bumetanide
,7738809,chloride excretion,"For example, the mean 8-h urine output values were 189, 317, 2170, and 306 mL for treatments I-IV, respectively, the corresponding 8-h sodium excretion values were 9.19, 16.5, 88.8, and 15.7 mmol, and the chloride excretion values were 10.8, 33.7, 77.4, and 11.7 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous bumetanide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738809/),mM,11.7,235017,DB00887,Bumetanide
,11011983,tmax,The tmax obtained ranged from 3 to 10 min.,Intranasal administration of different liquid formulations of bumetanide to rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011983/),min,3 to 10,239815,DB00887,Bumetanide
,11011983,bioavailability,The observed bioavailability for the different formulations ranged from 16 to 37% for the time period 0-120 min.,Intranasal administration of different liquid formulations of bumetanide to rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011983/),%,16 to 37,239816,DB00887,Bumetanide
,11011983,bioavailabilities,"Using this method bioavailabilities of 33-82, for the time interval 5-120 min was found.",Intranasal administration of different liquid formulations of bumetanide to rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011983/),,33-82,239817,DB00887,Bumetanide
,932937,limit of sensitivity,"Following extraction of the sample at pH 5.5 with ether, radioimmunoassay of the residue from the ether extract allows for the determination of bumetanide with a limit of sensitivity of about 1 ng/ml using 0.1 ml of plasma or urine.",Bumetanide: radioimmunoassay and pharmacokinetic profile in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/932937/),[ng] / [ml],1,243768,DB00887,Bumetanide
,932937,peak plasma levels,The peak plasma levels ranged from 39 to 50 ng/ml at 1-4 hr after administration and declined with a mean apparent half-life of 1.17 hr.,Bumetanide: radioimmunoassay and pharmacokinetic profile in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/932937/),[ng] / [ml],39 to 50,243769,DB00887,Bumetanide
,932937,apparent half-life,The peak plasma levels ranged from 39 to 50 ng/ml at 1-4 hr after administration and declined with a mean apparent half-life of 1.17 hr.,Bumetanide: radioimmunoassay and pharmacokinetic profile in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/932937/),h,1.17,243770,DB00887,Bumetanide
,932937,plasma clearance rate,The mean plasma clearance rate was calculated to be 255 ml/min.,Bumetanide: radioimmunoassay and pharmacokinetic profile in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/932937/),[ml] / [min],255,243771,DB00887,Bumetanide
,3430953,overall response,"Despite similarities in maximal fractional excretion of sodium (18.2 +/- 2.6% with furosemide vs. 19.4 +/- 4.5% with bumetanide, P = 0.687) demonstrating an equal tubular responsiveness to both drugs, overall response as quantified by cumulative natriuresis in the initial eight hour period was 52% greater with furosemide (108 +/- 17 vs. 71 +/- 7 mEq; P = 0.042).",Comparison of loop diuretics in patients with chronic renal insufficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3430953/),meq,108,243801,DB00887,Bumetanide
,3430953,overall response,"Despite similarities in maximal fractional excretion of sodium (18.2 +/- 2.6% with furosemide vs. 19.4 +/- 4.5% with bumetanide, P = 0.687) demonstrating an equal tubular responsiveness to both drugs, overall response as quantified by cumulative natriuresis in the initial eight hour period was 52% greater with furosemide (108 +/- 17 vs. 71 +/- 7 mEq; P = 0.042).",Comparison of loop diuretics in patients with chronic renal insufficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3430953/),meq,71,243802,DB00887,Bumetanide
,3430953,nonrenal clearance,"The difference in total excreted sodium was accounted for by a preserved nonrenal clearance of bumetanide (113 +/- 12 compared to 53 +/- 5 ml/min for furosemide, P = 0.001) which resulted in relatively less bumetanide in serum available to be delivered into the urine.",Comparison of loop diuretics in patients with chronic renal insufficiency. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3430953/),[ml] / [min],113,243803,DB00887,Bumetanide
,3430953,nonrenal clearance,"The difference in total excreted sodium was accounted for by a preserved nonrenal clearance of bumetanide (113 +/- 12 compared to 53 +/- 5 ml/min for furosemide, P = 0.001) which resulted in relatively less bumetanide in serum available to be delivered into the urine.",Comparison of loop diuretics in patients with chronic renal insufficiency. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3430953/),[ml] / [min],53,243804,DB00887,Bumetanide
,8392774,[K]p,"As [K]p was raised in steps from 2.6 +/- 0.2 to 7.9 +/- 0.2 mM, bicarbonate, chloride, and sodium reabsorption decreased by 232 +/- 56, 520 +/- 59 and 958 +/- 112 mumol min-1, respectively, at constant glomerular filtration rate (GFR).",Plasma potassium concentration as a determinant of proximal tubular NaCl and NaHCO3 reabsorption in dog kidneys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392774/),mM,2.6,255601,DB00887,Bumetanide
,8392774,[K]p,"As [K]p was raised in steps from 2.6 +/- 0.2 to 7.9 +/- 0.2 mM, bicarbonate, chloride, and sodium reabsorption decreased by 232 +/- 56, 520 +/- 59 and 958 +/- 112 mumol min-1, respectively, at constant glomerular filtration rate (GFR).",Plasma potassium concentration as a determinant of proximal tubular NaCl and NaHCO3 reabsorption in dog kidneys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392774/),mM,7.9,255602,DB00887,Bumetanide
,8392774,[K]p,"As [K]p was raised in steps from 2.6 +/- 0.2 to 7.9 +/- 0.2 mM, bicarbonate, chloride, and sodium reabsorption decreased by 232 +/- 56, 520 +/- 59 and 958 +/- 112 mumol min-1, respectively, at constant glomerular filtration rate (GFR).",Plasma potassium concentration as a determinant of proximal tubular NaCl and NaHCO3 reabsorption in dog kidneys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392774/),,520,255603,DB00887,Bumetanide
,8392774,[K]p,"As [K]p was raised in steps from 2.6 +/- 0.2 to 7.9 +/- 0.2 mM, bicarbonate, chloride, and sodium reabsorption decreased by 232 +/- 56, 520 +/- 59 and 958 +/- 112 mumol min-1, respectively, at constant glomerular filtration rate (GFR).",Plasma potassium concentration as a determinant of proximal tubular NaCl and NaHCO3 reabsorption in dog kidneys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392774/),,95,255604,DB00887,Bumetanide
,8392774,Fractional potassium reabsorption,Fractional potassium reabsorption remained constant at 0.31 +/- 0.03.,Plasma potassium concentration as a determinant of proximal tubular NaCl and NaHCO3 reabsorption in dog kidneys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392774/),,0.31,255605,DB00887,Bumetanide
,8392774,[K]p,"Administration of acetazolamide (100 mg kg-1 body wt) in eight dogs at [K]p 8 mM reduced fractional reabsorption of bicarbonate, chloride and sodium as much as in previous studies on normokalaemic dogs.",Plasma potassium concentration as a determinant of proximal tubular NaCl and NaHCO3 reabsorption in dog kidneys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392774/),mM,8,255606,DB00887,Bumetanide
,3608345,bioavailability,"Analysis of the areas under the curves showed a bioavailability of 0.84 +/- 0.2, which is similar to that in normal individuals.",Bioavailability of bumetanide in grossly oedematous patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608345/),,0.84,258824,DB00887,Bumetanide
,7153872,Renal clearance,Renal clearance (85 ml min-1) contributed 65% to the total elimination of bumetanide irrespective of whether a model-dependent or model-independent method was used.,The pharmacokinetics and pharmacodynamics of bumetanide in normal subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7153872/),[ml] / [min],85,259216,DB00887,Bumetanide
,3508546,ER50,"However, a consistent, demonstrable increase in ER50 (urinary excretion rate of drug producing 50% of Emax) was observed among Treatments I (2.34 micrograms/min), II (3.92 micrograms/min), and III (6.54 micrograms/min); also, a significant decrease in ER50 was observed between Treatment III (6.54 micrograms/min) and Treatment IV (2.66 micrograms/min).",Development of acute tolerance to bumetanide: bolus injection studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508546/),[μg] / [min],2.34,262011,DB00887,Bumetanide
,3508546,ER50,"However, a consistent, demonstrable increase in ER50 (urinary excretion rate of drug producing 50% of Emax) was observed among Treatments I (2.34 micrograms/min), II (3.92 micrograms/min), and III (6.54 micrograms/min); also, a significant decrease in ER50 was observed between Treatment III (6.54 micrograms/min) and Treatment IV (2.66 micrograms/min).",Development of acute tolerance to bumetanide: bolus injection studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508546/),[μg] / [min],3.92,262012,DB00887,Bumetanide
,3508546,ER50,"However, a consistent, demonstrable increase in ER50 (urinary excretion rate of drug producing 50% of Emax) was observed among Treatments I (2.34 micrograms/min), II (3.92 micrograms/min), and III (6.54 micrograms/min); also, a significant decrease in ER50 was observed between Treatment III (6.54 micrograms/min) and Treatment IV (2.66 micrograms/min).",Development of acute tolerance to bumetanide: bolus injection studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508546/),[μg] / [min],6.54,262013,DB00887,Bumetanide
,3508546,urinary excretion rate of drug,"However, a consistent, demonstrable increase in ER50 (urinary excretion rate of drug producing 50% of Emax) was observed among Treatments I (2.34 micrograms/min), II (3.92 micrograms/min), and III (6.54 micrograms/min); also, a significant decrease in ER50 was observed between Treatment III (6.54 micrograms/min) and Treatment IV (2.66 micrograms/min).",Development of acute tolerance to bumetanide: bolus injection studies. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508546/),[μg] / [min],2.34,262014,DB00887,Bumetanide
,3508546,urinary excretion rate of drug,"However, a consistent, demonstrable increase in ER50 (urinary excretion rate of drug producing 50% of Emax) was observed among Treatments I (2.34 micrograms/min), II (3.92 micrograms/min), and III (6.54 micrograms/min); also, a significant decrease in ER50 was observed between Treatment III (6.54 micrograms/min) and Treatment IV (2.66 micrograms/min).",Development of acute tolerance to bumetanide: bolus injection studies. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508546/),[μg] / [min],3.92,262015,DB00887,Bumetanide
,3508546,urinary excretion rate of drug,"However, a consistent, demonstrable increase in ER50 (urinary excretion rate of drug producing 50% of Emax) was observed among Treatments I (2.34 micrograms/min), II (3.92 micrograms/min), and III (6.54 micrograms/min); also, a significant decrease in ER50 was observed between Treatment III (6.54 micrograms/min) and Treatment IV (2.66 micrograms/min).",Development of acute tolerance to bumetanide: bolus injection studies. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508546/),[μg] / [min],6.54,262016,DB00887,Bumetanide
,3508546,ER50,"However, a consistent, demonstrable increase in ER50 (urinary excretion rate of drug producing 50% of Emax) was observed among Treatments I (2.34 micrograms/min), II (3.92 micrograms/min), and III (6.54 micrograms/min); also, a significant decrease in ER50 was observed between Treatment III (6.54 micrograms/min) and Treatment IV (2.66 micrograms/min).",Development of acute tolerance to bumetanide: bolus injection studies. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508546/),[μg] / [min],6.54,262017,DB00887,Bumetanide
,3508546,ER50,"However, a consistent, demonstrable increase in ER50 (urinary excretion rate of drug producing 50% of Emax) was observed among Treatments I (2.34 micrograms/min), II (3.92 micrograms/min), and III (6.54 micrograms/min); also, a significant decrease in ER50 was observed between Treatment III (6.54 micrograms/min) and Treatment IV (2.66 micrograms/min).",Development of acute tolerance to bumetanide: bolus injection studies. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508546/),[μg] / [min],2.66,262018,DB00887,Bumetanide
,2373133,urinary excretion,Similarly the urinary excretion of the gamma-hydroxybutyl metabolite was reduced from 6% in healthy subjects to 2.3% in patients with renal impairment.,Metabolism of the diuretic bumetanide in healthy subjects and patients with renal impairment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373133/),%,6,262447,DB00887,Bumetanide
,2373133,urinary excretion,Similarly the urinary excretion of the gamma-hydroxybutyl metabolite was reduced from 6% in healthy subjects to 2.3% in patients with renal impairment.,Metabolism of the diuretic bumetanide in healthy subjects and patients with renal impairment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373133/),%,2.3,262448,DB00887,Bumetanide
,702342,maximal fractional sodium excretion,"Under conditions of mild isotonic saline loading, significant diuresis was observed within 5 min after the injection of 25 and 250 microgram/kg of the drug, and with the higher dose, a maximal fractional sodium excretion of 34% was observed.",Renal effects of bumetanide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/702342/),%,34,264525,DB00887,Bumetanide
,6617067,lag time of absorption,In the fasting state a lag time of absorption of approximately 1 hr was followed by absorption t 1/2s and elimination t 1/2s of approximately 0.75 and 2 2.5 hr.,Azosemide kinetics and dynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),h,1,270323,DB00887,Bumetanide
,6617067,absorption t 1/2s,In the fasting state a lag time of absorption of approximately 1 hr was followed by absorption t 1/2s and elimination t 1/2s of approximately 0.75 and 2 2.5 hr.,Azosemide kinetics and dynamics. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),h,0.75,270324,DB00887,Bumetanide
,6617067,elimination t 1/2s,In the fasting state a lag time of absorption of approximately 1 hr was followed by absorption t 1/2s and elimination t 1/2s of approximately 0.75 and 2 2.5 hr.,Azosemide kinetics and dynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),h,0.75,270325,DB00887,Bumetanide
,6617067,elimination t 1/2s,In the fasting state a lag time of absorption of approximately 1 hr was followed by absorption t 1/2s and elimination t 1/2s of approximately 0.75 and 2 2.5 hr.,Azosemide kinetics and dynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),h,2 2.5,270326,DB00887,Bumetanide
,6617067,elimination t 1/2,After intravenous dosing the elimination t 1/2 was approximately 2 hr; 20% of a dose was recovered unchanged.,Azosemide kinetics and dynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),h,2,270327,DB00887,Bumetanide
,6617067,bioavailability,Thus azosemide has an estimated bioavailability of 10%.,Azosemide kinetics and dynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),%,10,270328,DB00887,Bumetanide
,6617067,dose inducing half-maximal response,"The relationship between urinary azosemide excretion rate (""dose"") and natriuretic response follows a sigmoid-shaped curve with a dose inducing half-maximal response of 9.3 +/- 2.6 micrograms/min, whereas it is 69.8, 12.1 and 1 microgram/min for furosemide, piretanide, and bumetanide respectively.",Azosemide kinetics and dynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),[μg] / [min],9.3,270329,DB00887,Bumetanide
,6617067,dose inducing half-maximal response,"The relationship between urinary azosemide excretion rate (""dose"") and natriuretic response follows a sigmoid-shaped curve with a dose inducing half-maximal response of 9.3 +/- 2.6 micrograms/min, whereas it is 69.8, 12.1 and 1 microgram/min for furosemide, piretanide, and bumetanide respectively.",Azosemide kinetics and dynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),[μg] / [min],69.8,270330,DB00887,Bumetanide
,6617067,dose inducing half-maximal response,"The relationship between urinary azosemide excretion rate (""dose"") and natriuretic response follows a sigmoid-shaped curve with a dose inducing half-maximal response of 9.3 +/- 2.6 micrograms/min, whereas it is 69.8, 12.1 and 1 microgram/min for furosemide, piretanide, and bumetanide respectively.",Azosemide kinetics and dynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),[μg] / [min],12.1,270331,DB00887,Bumetanide
,6617067,dose inducing half-maximal response,"The relationship between urinary azosemide excretion rate (""dose"") and natriuretic response follows a sigmoid-shaped curve with a dose inducing half-maximal response of 9.3 +/- 2.6 micrograms/min, whereas it is 69.8, 12.1 and 1 microgram/min for furosemide, piretanide, and bumetanide respectively.",Azosemide kinetics and dynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),[μg] / [min],1,270332,DB00887,Bumetanide
